Intellia Therapeutics, Inc. (NTLA): Price and Financial Metrics
NTLA Stock Summary
- With a price/sales ratio of 78.63, Intellia Therapeutics Inc has a higher such ratio than 95.88% of stocks in our set.
- With a year-over-year growth in debt of 113.9%, Intellia Therapeutics Inc's debt growth rate surpasses 90.5% of about US stocks.
- The volatility of Intellia Therapeutics Inc's share price is greater than that of 92.84% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Intellia Therapeutics Inc, a group of peers worth examining would be CRBP, MTEM, FIXX, RCUS, and VYGR.
- NTLA's SEC filings can be seen here. And to visit Intellia Therapeutics Inc's official web site, go to www.intelliatx.com.
NTLA Stock Price Chart Interactive Chart >
NTLA Price/Volume Stats
|Current price||$67.41||52-week high||$92.00|
|Prev. close||$67.33||52-week low||$12.32|
|Day high||$68.98||Avg. volume||1,615,511|
|50-day MA||$66.91||Dividend yield||N/A|
|200-day MA||$43.29||Market Cap||4.57B|
Intellia Therapeutics, Inc. (NTLA) Company Bio
Intellia Therapeutics a gene editing company, develops therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
NTLA Latest News Stream
|Loading, please wait...|
NTLA Latest Social Stream
View Full NTLA Social Stream
Latest NTLA News From Around the Web
Below are the latest news stories about Intellia Therapeutics Inc that investors may wish to consider to help them evaluate NTLA as an investment opportunity.
So what did the stock market do today?
A "sell" rating is one thing, but a price target barely half of the Thursday close?
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing.
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the company’s Board of Directors. “Dr. Keresty's experience as a scientific and operational leader in our industry will be a great asset to Intellia as we continue to advance our research programs, expand our manufacturing capabilities and move towards delivering potentially curative therapies to patients globally,” said Intellia President and Chief Executive Officer John Leonard, M.D. Dr. Keresty brings more than 35 years of pharmaceutical industry experience to Intellia’s board, including lea...
Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics
NTLA Price Returns
Continue Researching NTLAWant to see what other sources are saying about Intellia Therapeutics Inc's financials and stock price? Try the links below:
Intellia Therapeutics Inc (NTLA) Stock Price | Nasdaq
Intellia Therapeutics Inc (NTLA) Stock Quote, History and News - Yahoo Finance
Intellia Therapeutics Inc (NTLA) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!